Change in the Roche Board of Directors
Rhea-AI Summary
Roche (OTCQX: RHHBY) announced on 3 October 2025 that Dr. Claudia Süssmuth Dyckerhoff will not stand for re-election to the Roche Board at the 2026 Annual General Meeting. She has served on Roche's Board since March 2016 and will be nominated for election to the board of another company in the healthcare industry. Chairman Severin Schwan thanked her for a decade of contributions, citing her knowledge of healthcare and international market dynamics, particularly in Asia.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, RHHBY gained 1.34%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Basel, 3 October 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Dr. Claudia Süssmuth Dyckerhoff has decided not to stand for re-election as a member of the Roche Board of Directors at the Annual General Meeting in 2026. Instead she will be nominated for election to the board of another company which is serving the healthcare industry.
Dr. Süssmuth Dyckerhoff has served on the Board of Directors since March 2016.
Roche Chairman Severin Schwan: "Claudia’s profound knowledge of the healthcare industry and her deep understanding of international market dynamics, particularly in Asia, have resulted in significant contributions to the success of Roche. On behalf of the Board, I would like to sincerely thank Claudia for her dedication to Roche over the past decade and wish her all the best for the future.”
About Roche
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.
For over 125 years, sustainability has been an integral part of Roche’s business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045.
Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.
Roche Global Media Relations
Phone: +41 61 688 8888 / e-mail: media.relations@roche.com
| Hans Trees, PhD Phone: +41 79 407 72 58 | Sileia Urech Phone: +41 79 935 81 48 |
| Nathalie Altermatt Phone: +41 79 771 05 25 | Lorena Corfas Phone: +41 79 568 24 95 |
| Simon Goldsborough Phone: +44 797 32 72 915 | Karsten Kleine Phone: +41 79 461 86 83 |
| Kirti Pandey Phone: +49 172 6367262 | Yvette Petillon Phone: +41 79 961 92 50 |
| Dr Rebekka Schnell Phone: +41 79 205 27 03 |
Attachment
FAQ
Who announced the board change for Roche (RHHBY) on October 3, 2025?
When will Dr. Claudia Süssmuth Dyckerhoff leave the Roche board (RHHBY)?
How long has Dr. Claudia Süssmuth Dyckerhoff served on Roche's board (RHHBY)?
Will Dr. Claudia Süssmuth Dyckerhoff join another company after leaving Roche (RHHBY)?
Did Roche provide a reason or comment on Dr. Süssmuth Dyckerhoff's departure (RHHBY)?
Does the October 3, 2025 Roche (RHHBY) release indicate any immediate financial impact?
